iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-10 |
2024-03 |
0 |
N/A |
N/A |
N/A |
2024-02-09 |
2023-12 |
0 |
-2.42 |
N/A |
N/A |
2023-11-14 |
2023-09 |
0 |
-4.2 |
N/A |
N/A |
2023-10-10 |
2023-06 |
0 |
N/A |
N/A |
N/A |
2023-07-06 |
2023-03 |
0 |
N/A |
N/A |
N/A |
2023-02-14 |
2022-12 |
0 |
-21.6 |
N/A |
N/A |
Date |
Name |
Relation |
Quantity |
Description |
2023-10-31 |
BRENNER MARTIN |
Chief Executive Officer |
182.50K |
Sale |
2014-09-16 |
DESANTIS CARL R |
Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Sale |
2023-03-30 |
DURAN FELIPE |
Chief Financial Officer |
39.63K |
Stock Award(Grant) |
2020-08-10 |
EASTERN CAPITAL LTD |
Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Sale |
2020-06-03 |
ERWIN ROBERT L |
President |
108.11K |
Sale |
2020-03-18 |
ISETT THOMAS FRANCIS III |
Chief Executive Officer |
1.27M |
Conversion of Exercise of derivative security |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Group Inc |
512.28K |
312.49K |
1.86% |
2023-06-29 |
Avantax Planning Partners, Inc. |
155.00K |
94.55K |
0.56% |
2023-06-29 |
Blackrock Inc. |
137.94K |
84.14K |
0.50% |
2023-06-29 |
Bank Of New York Mellon Corporation |
87.47K |
53.36K |
0.32% |
2023-06-29 |
Geode Capital Management, LLC |
76.29K |
46.53K |
0.28% |
2023-06-29 |
Renaissance Technologies, LLC |
46.10K |
28.12K |
0.17% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
336.21K |
205.09K |
1.22% |
2023-06-29 |
Vanguard Extended Market Index Fund |
165.75K |
101.11K |
0.60% |
2023-05-30 |
Fidelity Extended Market Index Fund |
46.85K |
32.80K |
0.17% |
2023-05-30 |
Fidelity Total Market Index Fund |
13.73K |
9.61K |
0.05% |
2023-05-30 |
Fidelity Series Total Market Index Fund |
9.49K |
6.64K |
0.03% |
2023-06-29 |
Vanguard Institutional Index-Inst Total Stock Market Ind |
7.28K |
4.44K |
0.03% |
Split |
Date |
1 : 20 |
2023-11-29 |
1 : 25 |
2022-10-10 |
1 : 10 |
2018-06-11 |